Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Solid Tumors
Filter by Topic
Bladder Cancer
Breast Cancer
Colon Cancer
Colorectal Cancer
Gastric Cancer
Genitourinary Cancers
GI Cancers
Gynecologic Cancer
Head and Neck Cancer
Liver Cancer
Lung Cancer
Melanoma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Thyroid Cancer
The Long Road to Rehabilitation: Sandra Wade’s Story on Surviving Breast Cancer
By
Julie K. Silver, MD
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
,
The Patient Perspective
August 2014, Vol 5, No 6
Sandra Wade first e-mailed me on July 15, 2011. As you can see in the excerpts from her correspondence with me below, she asked me to contact her oncologist and let her know that as a breast cancer survivor, Sandra had suffered more than she should have, because she was not referred for rehabilitation services.
Read Article
ASCO Guidelines Target Advanced HER2-Positive Breast Cancer
By
Eileen Koutnik-Fotopoulos
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
June 2014, Vol 5, No 5
Approximately 15% to 20% of patients with breast cancer have HER2-positive disease. The American Society of Clinical Oncology (ASCO) released new clinical practice guidelines for the treatment of women with advanced HER2-positive breast cancer, focusing on systemic therapies.
Read Article
PSA Trend Analysis May Help Avoid Unnecessary Biopsies
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
June 2014, Vol 5, No 5
Orlando, FL—Delaying a prostate-specific antigen (PSA)-triggered prostate biopsy to allow for additional PSA assessments might have avoided more than 70% of subsequent biopsies, according to a study of negative biopsies for >28,000 men reported at the 2014 American Urological Association annual meeting.
Read Article
Enzalutamide Improves Survival After ADT in Patients with Metastatic CRPC
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
June 2014, Vol 5, No 5
Orlando, FL—Treatment with enzalutamide (Xtandi) after progression with androgen-deprivation therapy (ADT) led to a significant improvement in survival for men with metastatic castration-resistant prostate cancer (mCRPC), according to a new randomized trial reported at the 2014 American Urological Association annual meeting.
Read Article
Treatment Paradigm for Lung Cancer Shifting Toward Targeted Therapies, Immunotherapy
By
Wayne Kuznar
Lung Cancer
,
Personalized Medicine
,
Solid Tumors
May 2014, Vol 5, No 4
Hollywood, FL—Driver mutations, most frequently KRAS and EGFR, account for approximately 50% of non–small-cell lung cancer (NSCLC), and this recognition is shifting the NSCLC treatment paradigm toward targeted therapy when possible, said Leora Horn, MD, MSc, Assistant Professor of Medicine, Division of Hematology/ Oncology, Vanderbilt University, Nashville, TN, at the 2014 National Comprehensive Cancer Network Conference.
Read Article
Contrast-Enhanced Ultrasound a Promising, Inexpensive Diagnostic Tool for Prostate Cancer
By
Rosemary Frei, MSc
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
May 2014, Vol 5, No 4
Stockholm, Sweden—An inexpensive, noninvasive imaging modality is proving successful for verifying the presence of prostate cancer.
Read Article
Advances in the Treatment of Patients with Castration-Resistant Prostate Cancer
By
Wayne Kuznar
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
May 2014, Vol 5, No 4
Hollywood, FL—The treatment options for patients with castration-resistant prostate cancer (CRPC) have increased over the past few years. Understanding the clinical disease states is essential when choosing therapy for this patient population, according to Celestia S. Higano, MD, Professor of Medicine and Urology, University of Washington, Seattle, who described the recent additions to the therapeutic armamentarium at the 2014 National Comprehensive Cancer Network Conference.
Read Article
Benefits and Risks of Mammography Explored in New Analyses
By
Rosemary Frei, MSc
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
May 2014, Vol 5, No 4
According to a new systematic review of the risks and benefits of breast cancer screening, regular mammography is associated with a 19% reduction in breast cancer mortality, but it is also associated with a 61% cumulative risk of a false-positive result, and approximately 19% of the cases are, in fact, considered overdiagnoses (Pace LE, Keating NL.
JAMA
. 2014;311:1327-1335).
Read Article
New Guidelines Expand Pool of Patients Eligible for Sentinel Node Biopsy
By
Alice Goodman
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
May 2014, Vol 5, No 4
The American Society of Clinical Oncology (ASCO) has issued new guidelines for the use of sentinel node biopsy (SNB) in patients with early-stage breast cancer (Lyman GH, et al.
J Clin Oncol
. 2014;32:1365-1383. The newer version expands the use of SNB to a larger group of patients, based on evidence from 9 randomized trials and 13 cohort studies conducted since 2005, when the first SNB guidelines were published.
Read Article
Imaging Choice May Influence Brachytherapy Outcomes
By
Charles Bankhead
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
April 2014, Vol 5, No 3
San Francisco, CA—Magnetic resonance imaging (MRI)-guided brachytherapy led to significantly less urinary dysfunction in men being treated for localized prostate cancer compared with ultrasound-guided techniques, according to a long-term prospective cohort study reported at the 2014 Genitourinary Cancers Symposium.
Read Article
Page 11 of 16
6
7
8
9
10
11
12
13
14
15
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma